 Passage Bio NASDAQ: PASG shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and announced a 29 price target. The firm said the companys gene therapy platform and UPenn collaboration will create significant value for investors with multiple inflection events approaching in the next 6-12 months. 